Avid Bioservices Inc (CDMO)

[cjgaddy]

PPHM VP Dr. Jeff Hutchins presenting PS-Targeting Mabs in Immune Checkpoint Blockades session of CHI’s “Immunotherapies Congress” in Boston on Aug. 14th at 3pm…

Aug 13–15 2013: “CHI’s The Immunotherapies Congress”, Boston
Co-located with the 8th Annual “ImVacS” (Immunotherapeutics & Vaccine Summit) http://www.imvacs.com
2 INAUGURAL SUB-CONFERENCES:
• Aug13-14: Emerging Cancer Immunotherapies & Vaccines
• Aug14-15: Immunomodulatory Therapeutic Antibodies for Cancer <=PPHM's Dr. Hutchins Presenting
CHI = Cambridge Healthtech Inst. http://www.healthtech.com
Conf. website: http://www.immunotherapiescongress.com
http://www.immunotherapiescongress.com/Immunomodulatory-Antibodies-Cancer
”Recent advances in cancer immunotherapy have turned researcher's attentions to new therapeutic strategies focused on improved specificity, control of key checkpoints in immune response, the identification of new biomarkers and novel ways of combining therapies for maximum effect. The 2-conf. Immunotherapies Congress offers an exciting opportunity to learn how these strategies are being translated into the next generation of cancer immunotherapeutic drug products.”
…“Immunomodulatory Therapeutic Antibodies for Cancer” showcases the exciting wave of checkpoint blockades such as anti-PD-1 & anti-CTLA-4 now in clinical development – and explores considerations of trial design, drug safety, and biomarker discovery that will influence their application in patients.
- - - - - -
OVERVIEW: ”The recent approval of BMS's Yervoy (ipilumumab) and a succession of related programs advancing through clinical trials has generated increased interest in the development of antibody-based immunomodulators for cancer. Immunomodulatory Therapeutic Antibodies for Cancer will provide updates of clinical stage programs, and examine how these novel therapeutics influence trial design and the selection of clinical endpoints. Strategies for immune modulation that are most appropriate for targeting with antibodies will be considered, along with where combination regimens and new therapeutic formats can be effectively applied.”
- - - - - - - - - - -
PEREGRINE – Aug. 14 3:00pm:
Session: Immune Checkpoint Blockades
Presentation: “Engagement of Phosphatidylserine (PS) by PS-targeting Antibodies Blocks an Upstream Immunosuppressive Checkpoint in the Tumor Microenvironment; Inducing Multiple Downstream Anti-tumor Response Mechanisms”
Jeffrey T. Hutchins, PhD, VP, Preclinical Research
ABSTRACT:
The hallmark of apoptosis, phosphatidylserine (PS) exposure promotes non-inflammatory phagocytosis of dying native cells. This signaling pathway appears to be exploited by tumors resulting in the suppression of both innate and adaptive tumor immune responses. Administration of PS-targeting antibodies mediates pro-inflammatory cellular and cytokine responses that reverse this immunosuppressive checkpoint without the side-effects associated with systemic immune activation. Bavituximab is a late-stage clinical PS-targeting antibody that has demonstrated promising signs of anti-tumor activity and extended survival in patients with NSCLC and breast cancer.
- - - - - - - - -
Jeff T. Hutchins, VP, Preclinical Research - Dr. Hutchins was appointed VP of Preclinical Research in Sept. 2012. Prior to joining Peregrine, Jeff served for the last 5 of 11 years as VP, Pre-clinical Dev. at Inhibitex Inc, which was recently acquired by Bristol Meyers Squibb. . .
http://www.peregrineinc.com/about-us/management-team.html

= = = = = = = = = = = = = = = = = = = =
COMPANY UPDATES & ARTICLES: [ PPHM News: http://finance.yahoo.com/q/h?s=PPHM ]

7-11-13 Qtly. Conf. Call (King/Shan/Garnick/Lytle) Transcript http://tinyurl.com/khpokw6
...CEO S.King: “This [new bavi] moa insight has opened the door to completely new combinations not previously explored. Bavi acts on an upstream immune checkpoint, and thus, makes a potentially ideal combination with downstream-acting immune checkpoint inhibitors such as anti PD1 antibodies & CTLA-4 targeted approaches… Preclinical studies are well underway to explore these combinations, and we look forward to generating and reporting data later this year that could support moving these concepts into the clinic.”

6-27-13: Updates on Bavituximab Pgm. & Cash Position http://tinyurl.com/pmcgsgp
…“primary focus remains on the init. of the PhIII trial in 2nd-Line NSCLC by y/e; recent data supporting an immunotherapy moa for bavituximab opens many new development opportunities including new combinations not previously planned and has created a lot of excitement around the potential of bavituximab in combination with other immunotherapeutic agents…"